BioCentury
ARTICLE | Clinical News

Boehringer, Lilly report Phase III data for SGLT2 inhibitor

January 8, 2013 2:10 AM UTC

Boehringer Ingelheim GmbH (Ingelheim, Germany) and partner Eli Lilly and Co. (NYSE:LLY) said once-daily empagliflozin met the primary endpoint of reducing HbA1c from baseline to 24 weeks vs. placebo in four Phase III trials to treat Type II diabetes. The companies plan to submit regulatory applications for the sodium-glucose cotransporter 2 (SGLT2) inhibitor in the U.S. and EU in 1H13 and in Japan later this year. ...